Global Regulatory Landscape of Orphan Drug Development: An Evaluation of Market Authorizations, Therapeutic Areas and Sponsor Companies
TL;DR
This review provides a comprehensive overview of orphan drug development, global regulatory pathways, market authorization processes, and regulatory incentives across major regulatory authorities, while highlighting emerging opportunities such as artificial intelligence, gene therapy, precision medicine, and international regulatory collaboration.
Abstract
Rare diseases represent a significant global healthcare challenge due to their low prevalence, delayed diagnosis, limited treatment options, and high treatment costs. Orphan drugs have emerged as an essential therapeutic approach to address these unmet medical needs; however, their development and market authorization require specialized regulatory pathways and supportive incentives. This review provides a comprehensive overview of orphan drug development, global regulatory pathways, market authorization processes, and regulatory incentives across major regulatory authorities, including the United States Food and Drug Administration (USFDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), Therapeutic Goods Administration (TGA), and Central Drugs Standard Control Organisation (CDSCO). It further discusses the major challenges associated with orphan drug development, including clinical, regulatory, manufacturing, and market access barriers, while highlighting emerging opportunities such as artificial intelligence, gene therapy, precision medicine, and international regulatory collaboration. Overall, strengthening regulatory harmonization, fostering innovation, and enhancing global collaboration are essential to improve the development, approval, and accessibility of safe and effective orphan drugs for patients with rare diseases worldwide.